Data and publications reflect potential of REL-1017.

Our successful Phase 1 and 2 studies of REL-1017, combined with appreciation of the urgent need for additional effective and rapid-acting treatments, are fueling our ongoing Phase 3 registration studies focused on major depressive disorder (MDD). Learn more about our scientific findings and clinical program results to date.